Open AccessIncobotulinumtoxina (Xeomin)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.200
Subject(s) - reimbursement , medicine , political science , law , health care
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses incobotulinumtoxinA (Xeomin), powder for solution for injection, 50 and 100 units per vial.
Indication: For the treatment of chronic sialorrhea associated with neurologic disorders in adults.